Efficacy and safety of adjunctive topiramate for schizophrenia: a meta‐analysis of randomized controlled trials

托吡酯 随机对照试验 医学 内科学 耐受性 氯氮平 抗精神病药 荟萃分析 相对风险 安慰剂 置信区间 精神分裂症(面向对象编程) 精神科 不利影响 癫痫 病理 替代医学
作者
Wei Zheng,Yu‐Tao Xiang,Yingying Xiang,X.‐B. Li,G. S. Ungvari,Helen F.K. Chiu,Christoph Ulrich Correll
出处
期刊:Acta Psychiatrica Scandinavica [Wiley]
卷期号:134 (5): 385-398 被引量:68
标识
DOI:10.1111/acps.12631
摘要

OBJECTIVE: To systematically examine the randomized controlled trial (RCT) evidence regarding efficacy and tolerability of topiramate cotreatment with antipsychotics in schizophrenia-spectrum disorders. METHODS: Random-effects meta-analysis of RCTs of topiramate cotreatment with antipsychotics vs. placebo/ongoing antipsychotic treatment in schizophrenia-spectrum disorders. Standardized or weighted mean difference (SMD/WMD), risk ratio (RR) ±95% confidence intervals (CIs), and number needed to harm (NNH) were calculated. RESULTS: Across 16 RCTs (n = 934, duration = 11.8 ± 5.6 weeks), topiramate outperformed the comparator regarding change/endpoint of total (SMD: -0.58, 95% CI: -0.82, -0.35, P < 0.00001), positive (SMD: -0.37, 95% CI: -0.61, -0.14, P = 0.002), negative (SMD: -0.58, 95% CI: -0.87, -0.29, P < 0.0001), and general symptoms (SMD: -0.68, 95% CI: -0.95, -0.40, P < 0.00001). Furthermore, topiramate was superior regarding body weight (WMD: -2.75 kg, 95% CI: -4.03, -1.47, P < 0.0001), body mass index (BMI) (WMD: -1.77, 95% CI: -2.38, -1.15, P < 0.00001), triglycerides (P = 0.006), and insulin levels (P < 0.00001). Superiority regarding psychopathology and body weight/BMI was consistent across Chinese/Asian and Western RCTs, double-blind and open designs, clozapine and non-clozapine cotreatment, augmentation and co-initiation RCTs, and higher and lower quality RCTs. In meta-regression analyses, topiramate's efficacy for total symptoms was moderated by shorter illness duration (P = 0.047), while weight loss was greater in prevention/co-initiation vs. intervention/augmentation RCTs (-4.11 kg, 95% CI: -6.70, -1.52 vs. -1.41 kg, 95% CI: -2.23, -0.59, P < 0.001). All-cause discontinuation was similar between topiramate and comparators (RR: 1.28, 95% CI: 0.91, 1.81, P = 0.16). While topiramate led to more concentration/attention difficulties (P = 0.03, NNH = 8, 95% CI=4-25), psychomotor slowing (P = 0.02, NNH = 7, 95% CI = 4-25), and paresthesia (P = 0.05, NNH = 2, 95% CI = 4-33), it led to less ≥7% weight gain (P = 0.0001, NNH = 2, 95% CI = 2-3) and constipation (P = 0.04, NNH = 9, 95% CI = 5-100) than the comparator. CONCLUSIONS: These results indicate that adjunctive topiramate to antipsychotics is an effective and safe treatment choice for symptomatic improvement and weight reduction in patients with schizophrenia-spectrum disorders.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英俊的铭的应助被xiao采纳,获得10
刚刚
唐璜发布了新的文献求助10
刚刚
唐璜发布了新的文献求助10
刚刚
唐璜发布了新的文献求助10
刚刚
唐璜发布了新的文献求助10
刚刚
哈哈完成签到,获得积分10
刚刚
脑洞疼的应助被778采纳,获得10
1秒前
Lizhe发布了新的文献求助10
1秒前
双人余发布了新的文献求助10
1秒前
taotao发布了新的文献求助10
1秒前
孜然味的拜拜肉完成签到,获得积分10
2秒前
脑洞疼的应助被PhDL1采纳,获得10
2秒前
华仔的应助被王坤采纳,获得10
3秒前
高登登关注了科研通微信公众号
3秒前
赘婿的应助被Lizhe采纳,获得10
5秒前
HKgryifho发布了新的文献求助10
5秒前
qzy完成签到,获得积分10
5秒前
摩登C位发布了新的文献求助10
6秒前
草莓酱完成签到,获得积分10
7秒前
7秒前
Owen的应助被xxxx采纳,获得10
7秒前
7秒前
7秒前
7秒前
上官若男的应助被太清采纳,获得10
7秒前
8秒前
9秒前
taotao完成签到,获得积分10
9秒前
9秒前
circusZ发布了新的文献求助10
10秒前
CarryLJR的应助被twistzz采纳,获得10
10秒前
11秒前
思源的应助被SG采纳,获得10
11秒前
11秒前
cwm发布了新的文献求助10
12秒前
斯文败类的应助被请问采纳,获得10
13秒前
14秒前
刘佳琦19947完成签到,获得积分10
14秒前
14秒前
CarryLJR的应助被小村采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178617
求助须知:如何正确求助?哪些是违规求助? 9569413
关于积分的说明 21804370
捐赠科研通 7773649
什么是DOI,文献DOI怎么找? 3432878
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478478